📰 Nasdaq Avte News
Nasdaq Avte News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Avte. Real-time updates on events, politics, business and more.
May 5, 2024
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) CEO Timothy P. Noyes sold 11,357 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $20.34, for a total transaction of $231,001.38. The sale was disclosed in a filing with the Securities & Exchange Commission, […]
April 24, 2024
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) shares saw strong trading volume on Wednesday . 197,194 shares traded hands during trading, an increase of 52% from the previous session’s volume of 129,738 shares.The stock last traded at $22.91 and had previously closed at $23.22. Wall Street Analysts Forecast Growth A number of research analysts […]
April 6, 2024
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) CEO Timothy P. Noyes sold 10,000 shares of Aerovate Therapeutics stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $30.00, for a total value of $300,000.00. The transaction was disclosed in a filing with the SEC, which […]
April 5, 2024
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report)’s share price dropped 3.9% on Wednesday after an insider sold shares in the company. The company traded as low as $28.23 and last traded at $28.44. Approximately 5,463 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 121,717 shares. The […]
April 1, 2024
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) hit a new 52-week high during trading on Monday . The company traded as high as $30.73 and last traded at $28.72, with a volume of 14079 shares. The stock had previously closed at $29.57. Analyst Upgrades and Downgrades A number of equities research analysts have recently […]
March 28, 2024
Jefferies Financial Group started coverage on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $65.00 price target on the stock. Separately, Wells Fargo & Company initiated coverage on shares of Aerovate Therapeutics in a research […]
March 26, 2024
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report)’s share price fell 8.8% during mid-day trading on Tuesday . The company traded as low as $24.27 and last traded at $24.58. 36,947 shares were traded during mid-day trading, a decline of 63% from the average session volume of 100,754 shares. The stock had previously closed at […]
March 25, 2024
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) reached a new 52-week high on Monday . The company traded as high as $28.39 and last traded at $27.85, with a volume of 25873 shares trading hands. The stock had previously closed at $25.78. Analysts Set New Price Targets AVTE has been the subject of several […]
March 25, 2024
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial...
February 23, 2024
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) insider Hunter Gillies sold 3,489 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $20.23, for a total transaction of $70,582.47. Following the transaction, the insider now directly owns 3,251 shares of the company’s stock, […]